United Therapeutics (UTHR) Net Cash Flow Growth (1y) (2010 - 2026)
Powered by 
Analysis
United Therapeutics (UTHR) Net Cash Flow Growth (1y) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.95 Bn | 625.20 Bn | 17.26 Bn | 93.66% |
| 2 | AbbVie | 441.39 Bn | 434.82 Bn | 12.70 Bn | -323.06% |
| 3 | Merck | 366.72 Bn | 359.58 Bn | 12.21 Bn | 248.11% |
| 4 | Novartis Ag | 266.68 Bn | 258.99 Bn | 11.24 Bn | 195.58% |
| 5 | Pfizer | 159.20 Bn | 147.50 Bn | 10.94 Bn | -517.34% |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn | -88.52% |
| 7 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 8 | Incyte | 25.50 Bn | 20.96 Bn | 1.57 Bn | 3,465.10% |
| 9 | United Therapeutics | 21.54 Bn | 18.88 Bn | 683.80 Mn | 270.63% |
| 10 | Neurocrine Biosciences | 15.60 Bn | 15.21 Bn | 935.80 Mn | -7.60% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 270.63% |
| Mar 31, 2026 | -236.85% |
| Dec 31, 2025 | 51.43% |
| Sep 30, 2025 | -227.65% |
| Jun 30, 2025 | -394.43% |
| Mar 31, 2025 | 362.79% |
| Dec 31, 2024 | 43.30% |
| Sep 30, 2024 | 390.59% |
| Jun 30, 2024 | 208.32% |
| Mar 31, 2024 | -78.35% |
| Dec 31, 2023 | 1,885.71% |
| Sep 30, 2023 | -76.46% |
| Jun 30, 2023 | -431.49% |
| Mar 31, 2023 | 348.22% |
| Dec 31, 2022 | 59.12% |
| Sep 30, 2022 | 609.20% |
| Jun 30, 2022 | -116.47% |
| Mar 31, 2022 | -187.07% |
| Dec 31, 2021 | -120.00% |
| Sep 30, 2021 | -121.71% |